Atezolizumab
Based on 38 publication(s) in Google Scholar
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.9%
- CAS No.: 1380723-44-3
- 분자량:144.6 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Atezolizumab
More- Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
- Cell Res. 2025 Aug;35(8):588-606. [Abstract]
- Nat Commun. 2026 Apr 23;17(1):5600. [Abstract]
- Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
- Adv Sci (Weinh). 2024 May 22:e2309992. [Abstract]
- Biomaterials. 2024 Jul:308:122550. [Abstract]
- Sci Adv. 2023 Apr 7;9(14):eade9944. [Abstract]
- Cell Discov. 2023 Feb 21;9(1):20. [Abstract]
- Clin Cancer Res. 2023 Dec 15;29(24):5227-5243. [Abstract]
- Cancer Lett. 2025 Jan 18:217475. [Abstract]
- Cell Rep. 2022 Feb 8;38(6):110349. [Abstract]
- J Med Chem. 2024 Mar 14;67(5):4036-4062. [Abstract]
- Int J Nanomedicine. 2023 Sep 8:18:5141-5157. [Abstract]
- JCI Insight. 2025 Feb 25;10(7):e187025. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Front Immunol. 2025 Sep 5:16:1658679. [Abstract]
- Lab Chip. 2025 Apr 10. [Abstract]
- Inflammation. 2021 Aug;44(4):1441-1451. [Abstract]
- Pharmaceuticals (Basel). 2023 Jul 24;16(7):1051. [Abstract]
- Bioorg Chem. 2023 Dec:141:106912. [Abstract]
- Biomed J. 2026 Jun 10:101002. [Abstract]
- Cancers (Basel). 2025 Oct 23;17(21):3411. [Abstract]
- Lab Invest. 2023 Jul;103(7):100148. [Abstract]
- Biomed Mater. 2021 Mar 8;16(4). [Abstract]
- Front Biosci (Landmark Ed). 2025 Aug 30;30(8):42844. [Abstract]
- Cell Biol Int. 2024 Oct;48(10):1588-1598. [Abstract]
- EJNMMI Res. 2022 Oct 28;12(1):70. [Abstract]
- EJNMMI Res. 2020 Jun 15;10(1):64. [Abstract]
- Mol Imaging Biol. 2020 Aug;22(4):842-853. [Abstract]
- Mol Imaging. 2024 Jun 14:23:15353508241261473. [Abstract]
- Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556. [Abstract]
- Cancer Invest. 2021 Jul-Aug;39(6-7):571-581. [Abstract]
- JPN J APPL PHYS. 2023 Feb 6.
- STAR Protoc. 2025 Apr 14;6(2):103767. [Abstract]
- J Labelled Comp Radiopharm. 2024 Sep;67(11):384-391. [Abstract]
- Research Square Print. 2022 Aug.
- Research Square Preprint. 2021 Mar.
- Patent. US20200253884A1.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Flow Cytometry
-
WB
-
Histological Imaging/Staining
-
In Vivo Imaging
Biological Activity
Human IgG1 kappa
Human
B7-H1/PD-L1/CD274
Atezolizumab (0, 2.5, 5, 10, 20, and 40 μg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells[1].
Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway[1].
Atezolizumab (10 μg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized PD-L1 Protein, Human (HEK293) can bind Atezolizumab. The EC 50 for this effect is 10.9 ng/mL. -
Chemical Information
-
CAS No. 1380723-44-3
-
Appearance Liquid
-
분자량 144.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Atezolizumab]
-
Synonyms
MPDL3280A; RG-7446; RO-5541267
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (38)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
2025 Feb;20(2):296-302. PMID: 39468359
Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
PD-L1 expression levels in 293T cells overexpressing PD-L1 after treatment with 500 nM ATZ and ATZ-NPs for 24 h. Vinculin (VINC) was utilized as a loading control.
-
Cell Res
Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progression. [Abstract]2025 Aug;35(8):588-606. PMID: 40664963 -
Nat Commun
High-throughput single-vesicle imaging platform for direct extracellular vesicle profiling of human plasma. [Abstract]2026 Apr 23;17(1):5600. PMID: 42020418 -
Nat Commun
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]2025 Nov 18;16(1):10096. PMID: 41253833
Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.
Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45+ cells), anti-CD68/CD80-stained macrophages (gated on CD45+ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45+ Lin-1- T cells), and anti-CD3/CD8-stained T cells (gated on CD45+ cells) in tumor tissues after different treatments (n = 5 independent mice).
-
Adv Sci (Weinh)
Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy. [Abstract]2024 May 22:e2309992. PMID: 38774946
Atezolizumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 May 22:e2309992. [Abstract]
Atezolizumab (100 μg/mouse; i.p.; at days 2, 4, and 6). H&E staining, cleaved-caspase 3, Ki 67, CXCR4 and PD-L1 IHC staining images of tumor slices after various treatments. Group A received PBS. Group B received PBS + ICT (Atezolizumab). Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.
Atezolizumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 May 22:e2309992. [Abstract]
Atezolizumab (100 μg/mouse; i.p.; at days 2, 4, and 6). Images of mice and excised tumor after different treatments. Group A received PBS. Group B received PBS + ICT (Atezolizumab). Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.
-
Biomaterials
Bispecific fibrous glue synergistically boosts vascular normalization and antitumor immunity for advanced renal carcinoma therapy. [Abstract]2024 Jul:308:122550. PMID: 38581762 -
Sci Adv
Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response. [Abstract]2023 Apr 7;9(14):eade9944. PMID: 37027467 -
Cell Discov
MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. [Abstract]2023 Feb 21;9(1):20. PMID: 36810288 -
Clin Cancer Res
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer. [Abstract]2023 Dec 15;29(24):5227-5243. PMID: 37831062 -
Cancer Lett
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity. [Abstract]2025 Jan 18:217475. PMID: 39828123 -
Cell Rep
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II. [Abstract]2022 Feb 8;38(6):110349. PMID: 35139382 -
J Med Chem
Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1. [Abstract]2024 Mar 14;67(5):4036-4062. PMID: 38442487 -
Int J Nanomedicine
Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer. [Abstract]2023 Sep 8:18:5141-5157. PMID: 37705867 -
JCI Insight
2025 Feb 25;10(7):e187025. PMID: 39998891 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Front Immunol
CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway. [Abstract]2025 Sep 5:16:1658679. PMID: 40977688 -
Lab Chip
A novel microfluidic self-perfusion chip (MSPC) for pumpless 3D cell, microtissue and organoid culture. [Abstract]2025 Apr 10. PMID: 40206017 -
Inflammation
PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis. [Abstract]2021 Aug;44(4):1441-1451. PMID: 33598777 -
Pharmaceuticals (Basel)
On the Road towards Small-Molecule Programmed Cell Death 1 Ligand 1 Positron Emission Tomography Tracers: A Ligand-Based Drug Design Approach. [Abstract]2023 Jul 24;16(7):1051. PMID: 37513962 -
Bioorg Chem
2023 Dec:141:106912. PMID: 37839142 -
Biomed J
2026 Jun 10:101002. PMID: 42270077 -
Cancers (Basel)
Targeted Hyaluronan Degradation Enhanced Tumor Growth Inhibition in Gastrointestinal Cancer Models. [Abstract]2025 Oct 23;17(21):3411. PMID: 41228205 -
Lab Invest
Androgen receptor transcriptionally inhibits programmed death ligand-1 (PD-L1) expression and influences immune escape in bladder cancer. [Abstract]2023 Jul;103(7):100148. PMID: 37059268 -
Biomed Mater
A photoactivatable antibody-Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy. [Abstract]2021 Mar 8;16(4). PMID: 32584266 -
Front Biosci (Landmark Ed)
Immune Characteristics of eQTL and Gene Risk Model and the Inhibitory Effect of DCTD and RRAS on Ferroptosis in Glioblastoma. [Abstract]2025 Aug 30;30(8):42844. PMID: 40917066 -
Cell Biol Int
AML cell-derived exosomes suppress the activation and cytotoxicity of NK cells in AML via PD-1/PD-L1 pathway. [Abstract]2024 Oct;48(10):1588-1598. PMID: 39030886 -
EJNMMI Res
Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer. [Abstract]2022 Oct 28;12(1):70. PMID: 36307610 -
EJNMMI Res
Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo. [Abstract]2020 Jun 15;10(1):64. PMID: 32542442
Atezolizumab purchased from MedChemExpress. Usage Cited in: EJNMMI Res. 2020 Jun 15;10(1):64. [Abstract]
Western blot analysis of total cell lysates using anti-PD-L1 (Atezolizumab, 6.91 nM) and anti-β-actin antibody between LoVo, LS174T, SW620, and RKO in vitro.
-
Mol Imaging Biol
A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. [Abstract]2020 Aug;22(4):842-853. PMID: 31741201 -
Mol Imaging
Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging. [Abstract]2024 Jun 14:23:15353508241261473. PMID: 38952401 -
Korean J Physiol Pharmacol
Gaseous signal molecule SO2 regulates autophagy through PI3K/AKT pathway inhibits cardiomyocyte apoptosis and improves myocardial fibrosis in rats with type II diabetes. [Abstract]2022 Nov 1;26(6):541-556. PMID: 36302628 -
Cancer Invest
Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice. [Abstract]2021 Jul-Aug;39(6-7):571-581. PMID: 34148483 -
-
STAR Protoc
Protocol to co-culture SCLC cells with human CD8+ T cells to measure tumor cell killing and T cell activation. [Abstract]2025 Apr 14;6(2):103767. PMID: 40232937 -
J Labelled Comp Radiopharm
Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo. [Abstract]2024 Sep;67(11):384-391. PMID: 39210726 -
-
-
순도&문서
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42(3):484-7. [Content Brief]
[2]. Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12(2):164. Published 2021 Feb 8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz